{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T12:00:23Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 25.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0957c-4a92-7bd1-8951-7a55921eff1b\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: pergolide\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regis", "usd": 0.0, "recall": true }, "codex": { "seconds": 78.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0957c-4a8a-7602-87fc-c58da6d6c869\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: pergolide\nRegistry id: vr.tr.pergolide\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCont" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:54:52+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q415752", "registryId": "vr.tr.pergolide", "name": "pergolide", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q415752/", "model": { "registry_id": "vr.tr.pergolide", "name": "pergolide", "purpose": "Enable an agent to identify pergolide, assess the identity and fitness of a particular material, and determine which handling or use decisions require additional evidence.", "definition": "Pergolide is a synthetic ergot-derived dopamine-receptor agonist, commonly formulated as its mesylate salt, formerly used to treat Parkinson's disease in humans and used in veterinary medicine to manage equine pituitary pars intermedia dysfunction.", "scope_statement": "This model owns pergolide as the chemical entity registered at vr.tr.pergolide in PHY / PHY.MAT, including its stereochemical identity, material quality, pharmacological properties, and relationships to salts and regulated products.", "in_scope": [ "Pergolide molecular identity and stereochemistry", "Distinction between pergolide free base and pergolide mesylate", "Material composition, assay basis, impurities, and physical state", "Condition-dependent stability and handling requirements", "Pharmacological activity and safety evidence", "Jurisdiction-, species-, and product-specific use constraints" ], "out_of_scope": [ "Finished medicine formulations, packaging, and product inventories", "Individual human or animal diagnosis, prescribing, and treatment plans", "Parkinson disease and equine pituitary pars intermedia dysfunction as disease models", "Chemical synthesis routes and manufacturing equipment", "Other dopamine agonists as independently identified substances" ], "distinguishing_features": [ "Match the molecular structure and stereochemistry associated with pergolide free base, PubChem CID 47811 and CAS 66104-22-1; a name match alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Pergolide)", "Check for a mesylate counterion before assigning free-base identifiers or interpreting weighed mass; marketed formulations may contain pergolide mesylate, a separately identified salt. [IUPHAR/BPS](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=48)", "Distinguish pergolide's ergoline structure, N-propyl substitution, and methylthiomethyl group from structurally related dopamine agonists. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Pergolide)", "Distinguish a quantity of active pergolide from the total mass of its salt or a tablet; the FDA approval summary describes tablets containing 1.0 mg pergolide as pergolide mesylate. [FDA](https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/890)" ], "characteristics": [ { "name": "Molecular identity", "kind": "category", "unit_or_values": "Structure with explicit stereochemistry; free-base formula C19H26N2S; CID 47811", "why_it_matters": "Anchors recognition to a chemical entity rather than a trade name. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Pergolide)" }, { "name": "Chemical form", "kind": "category", "unit_or_values": "Free base; mesylate salt; other documented form; unresolved", "why_it_matters": "Controls identifier assignment, mass interpretation, and applicability of material data." }, { "name": "Pergolide content", "kind": "measurement", "unit_or_values": "mg/g, mg/mL, or mass %, with free-base or salt basis and analytical method", "why_it_matters": "Prevents confusion between active-moiety content and total material mass." }, { "name": "Impurity and stereochemical profile", "kind": "measurement", "unit_or_values": "Individual impurity %, stereoisomer %, method, detection limits, and acceptance specification", "why_it_matters": "Makes suitability depend on measured composition and intended grade." }, { "name": "Material grade", "kind": "category", "unit_or_values": "Reference standard; research material; pharmaceutical ingredient; other documented grade; unknown", "why_it_matters": "Separates identity confirmation from qualification for a particular use." }, { "name": "Physical state and properties", "kind": "measurement", "unit_or_values": "Phase; melting or decomposition temperature in °C; solubility in mg/mL with solvent, pH, and temperature", "why_it_matters": "Prevents transferring constants between free base, salt, and formulation without justification." }, { "name": "Storage and stability status", "kind": "state", "unit_or_values": "Within supported conditions; excursion pending assessment; retest required; expired; unknown", "why_it_matters": "Connects environmental history and stability evidence to continued suitability." }, { "name": "Receptor activity", "kind": "measurement", "unit_or_values": "Target, species, assay type, Ki or EC50 in nM, and efficacy where measured", "why_it_matters": "Keeps binding affinity, functional agonism, and clinical effects distinct." }, { "name": "Hazard classification", "kind": "category", "unit_or_values": "Documented classification, chemical form, jurisdiction, source revision, or unresolved", "why_it_matters": "Supports handling decisions without treating therapeutic risk as an automatically equivalent GHS classification." }, { "name": "Regulated-use relationship", "kind": "relation", "unit_or_values": "Product, jurisdiction, species, indication, authorization status, and effective date", "why_it_matters": "Prevents a historical or veterinary authorization from being generalized to every use of pergolide." } ], "affordances": [ "Resolve a supplied identifier or certificate to pergolide and its documented chemical form.", "Normalize pergolide quantities only when salt stoichiometry, purity, and reporting basis are established.", "Compare lot-specific analytical results with the specification required for an intended use.", "Assess whether storage history requires quarantine, retesting, or rejection under an applicable procedure.", "Retrieve pharmacological and safety evidence with its species and experimental context.", "Check a proposed use against dated jurisdictional and product records and route unresolved decisions to a qualified reviewer." ], "agent_conduct": { "may": [ "Identify pergolide and explain its veterinary use and withdrawal from human use in several countries, citing sources.", "Report stock, expiry and labelling of a veterinary product to its holder." ], "must_not": [ "Recommend pergolide for a person.", "Recommend dosing a horse or other animal without a veterinarian's prescription.", "Present a human product as interchangeable with a veterinary product.", "Dismiss reported adverse effects in treated animals." ], "requires_human": [ "Any treatment decision for an animal.", "Disposing of veterinary stock." ] }, "ethics": { "considerations": [ "Human use was withdrawn in several countries over heart-valve risks, so it must not be suggested for people.", "Treated horses depend on owners and vets for their welfare." ], "affected_parties": [ "Horses and their owners", "Veterinarians", "People handling tablets" ] }, "owners": { "steward": "The veterinarian or animal keeper holding it; the veterinary medicines regulator authorizes its use.", "master_systems": [ "National veterinary medicines registers" ] }, "visual_identification": [ "As a veterinary medicine, tablets in labelled packs stating the active substance.", "Cannot be identified by appearance; the label and analysis settle identity." ], "failure_modes_and_hazards": [ "Accidental exposure of people handling tablets.", "Adverse effects in animals when used without veterinary oversight." ], "standards_and_regulation": [ "Globally Harmonized System of Classification and Labelling of Chemicals (GHS), United Nations." ], "what_it_is_for": [ "Pergolide is encountered in veterinary medicines used to manage equine pituitary pars intermedia dysfunction.", "It also appears in historical Parkinson's disease treatment records and pharmacological research concerning dopamine receptors.", "Assessment of a material distinguishes the active compound, its salt form and the finished medicinal product." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q415752: pergolide", "url": "https://www.wikidata.org/wiki/Q415752", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Pergolide", "url": "https://en.wikipedia.org/wiki/Pergolide", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "chemical-identity", "name": "Chemical identity", "description": "Establish which pergolide entity a record or material represents.", "rationale": "Pergolide names can refer to an active moiety, a salt, or a medicine containing it.", "layers": [ { "id": "structure-recognition", "name": "Structure recognition", "description": "Identify pergolide through structure and stereochemistry.", "findings": [ { "id": "identity-anchor", "name": "Identity anchor", "description": "Use a stereochemically explicit structure and authoritative identifiers as the recognition anchor.", "questions": [ { "text": "Which structure and stereochemical specification define pergolide in this record?", "kind": "definition", "id": "identity-anchor-q01" }, { "text": "Which authoritative record supports each identifier, and do all identifiers resolve to the same chemical form?", "kind": "provenance", "id": "identity-anchor-q02" } ] } ] }, { "id": "salt-and-product-boundaries", "name": "Salt and product boundaries", "description": "Represent related forms without conflating their identities.", "findings": [ { "id": "free-base-versus-mesylate", "name": "Free base versus mesylate", "description": "Record the mesylate relationship explicitly and preserve the registry entry's granularity.", "questions": [ { "text": "Does the material contain pergolide free base, its mesylate salt, or a formulation containing that salt?", "kind": "boundary", "id": "free-base-versus-mesylate-q01" }, { "text": "Which counterion, stoichiometry, and identifier evidence establish the supplied form?", "kind": "measurement", "id": "free-base-versus-mesylate-q02" } ] } ] } ] }, { "id": "composition-and-qualification", "name": "Composition and qualification", "description": "Determine how much pergolide is present and whether the material meets a stated purpose.", "rationale": "Chemical identity alone cannot establish potency, purity, or suitability.", "layers": [ { "id": "content-basis", "name": "Content basis", "description": "Make pergolide quantities interpretable across salt and active-moiety reporting.", "findings": [ { "id": "assay-normalization", "name": "Assay normalization", "description": "Every content value needs a chemical basis, sample basis, and measurement method.", "questions": [ { "text": "Is the reported assay expressed as pergolide free-base equivalent or pergolide mesylate, and on an as-is or corrected basis?", "kind": "measurement", "id": "assay-normalization-q01" }, { "text": "What verified composition and calculation permit conversion between the reported and required quantities?", "kind": "action", "id": "assay-normalization-q02" } ] } ] }, { "id": "lot-qualification", "name": "Lot qualification", "description": "Connect analytical evidence to an intended material grade.", "findings": [ { "id": "purity-and-release", "name": "Purity and release", "description": "Qualification requires lot-specific impurity evidence and an applicable acceptance specification.", "questions": [ { "text": "Which related substances, stereoisomers, residual solvents, and other relevant impurities were measured, with what limits?", "kind": "measurement", "id": "purity-and-release-q01" }, { "text": "Which specification and certificate support this lot's claimed grade and permitted use?", "kind": "provenance", "id": "purity-and-release-q02" } ] } ] } ] }, { "id": "physical-state-and-stability", "name": "Physical state and stability", "description": "Track the conditions under which a pergolide material remains characterized and usable.", "rationale": "Physical constants and storage instructions must apply to the actual chemical form and presentation.", "layers": [ { "id": "form-specific-properties", "name": "Form-specific properties", "description": "Attach physical measurements to an identified material and test conditions.", "findings": [ { "id": "qualified-physical-data", "name": "Qualified physical data", "description": "Treat phase, thermal behavior, and solubility as conditional observations rather than universal name-level constants.", "questions": [ { "text": "For which pergolide form, purity, and conditions were phase, solubility, and thermal behavior measured?", "kind": "measurement", "id": "qualified-physical-data-q01" }, { "text": "Does a reported thermal value describe melting, decomposition, or another transition?", "kind": "definition", "id": "qualified-physical-data-q02" } ] } ] }, { "id": "storage-history", "name": "Storage history", "description": "Evaluate material condition against applicable stability evidence.", "findings": [ { "id": "stability-disposition", "name": "Stability disposition", "description": "Storage limits and retest decisions must be supported for the material form and container involved.", "questions": [ { "text": "What evidence establishes temperature, light, moisture, container, and retest requirements for this pergolide material?", "kind": "provenance", "id": "stability-disposition-q01" }, { "text": "Does the recorded exposure history permit continued use, or require quarantine and analytical reassessment?", "kind": "action", "id": "stability-disposition-q02" } ] } ] } ] }, { "id": "pharmacology-and-hazards", "name": "Pharmacology and hazards", "description": "Connect pergolide's biological activity to evidence-qualified safety constraints.", "rationale": "Dopamine agonism does not by itself describe pergolide's full biological or safety profile.", "layers": [ { "id": "target-activity", "name": "Target activity", "description": "Separate receptor-level measurements from organism-level outcomes.", "findings": [ { "id": "activity-evidence", "name": "Activity evidence", "description": "Record dopamine and other receptor evidence with assay context rather than treating agonist labels as interchangeable potency values.", "questions": [ { "text": "Which dopamine and serotonin receptor activities are established for pergolide, in which species and assays?", "kind": "measurement", "id": "activity-evidence-q01" }, { "text": "Does each result measure binding, functional activation, or an in vivo outcome?", "kind": "boundary", "id": "activity-evidence-q02" } ] } ] }, { "id": "risk-context", "name": "Risk context", "description": "Keep clinical adverse effects and material-handling hazards traceable to their respective evidence.", "findings": [ { "id": "valvular-and-handling-risk", "name": "Valvular and handling risk", "description": "FDA records associate pergolide mesylate with heart-valve damage and document the 2007 US market withdrawal announcement; occupational classifications require separate evidence. [Federal Register](https://public-inspection.federalregister.gov/2014-15371.pdf?1404218983=)", "questions": [ { "text": "What population, exposure, and evidence support each reported pergolide adverse effect, including valvular risk?", "kind": "provenance", "id": "valvular-and-handling-risk-q01" }, { "text": "Which current safety data sheet and applicable exposure controls cover the exact material being handled?", "kind": "action", "id": "valvular-and-handling-risk-q02" } ] } ] } ] }, { "id": "regulated-use-context", "name": "Regulated use context", "description": "Determine how pergolide relates to authorized products and proposed uses.", "rationale": "Historical human use and veterinary product approval create distinct regulatory contexts.", "layers": [ { "id": "authorization-records", "name": "Authorization records", "description": "Locate dated decisions for a jurisdiction, species, and product.", "findings": [ { "id": "species-specific-status", "name": "Species-specific status", "description": "Store authorizations and withdrawals as scoped records; the FDA's 2011 PRASCEND approval summary provides an equine product reference. [FDA](https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/890)", "questions": [ { "text": "Which current authority record governs the proposed pergolide product, species, indication, and jurisdiction?", "kind": "provenance", "id": "species-specific-status-q01" }, { "text": "Is the cited record a historical approval, withdrawal, current authorization, or another regulatory decision?", "kind": "definition", "id": "species-specific-status-q02" } ] } ] }, { "id": "use-eligibility", "name": "Use eligibility", "description": "Connect substance evidence to a proposed action without assuming prescribing authority.", "findings": [ { "id": "decision-prerequisites", "name": "Decision prerequisites", "description": "A proposed use requires matching material qualification, product context, and applicable restrictions.", "questions": [ { "text": "Does the proposed action concern research material, pharmaceutical manufacture, or administration of a specific medicine?", "kind": "boundary", "id": "decision-prerequisites-q01" }, { "text": "Which unresolved qualification, species restriction, or authorization condition prevents the action from proceeding?", "kind": "action", "id": "decision-prerequisites-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information, not a source-verified record; confirm identifiers and jurisdiction-specific authorization before publication.", "Melting behavior, solubility, stability and purity specifications require identification of the exact salt, solid form and test conditions.", "Human adverse-effect evidence should not be assumed to establish the same incidence or severity in horses." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Pergolide free base", "Pergolide mesylate" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "pergolide", "note": "Names the active substance rather than a particular medicinal product." }, { "scheme": "CAS Registry Number", "value_or_pattern": "66104-22-1", "note": "Identifies pergolide free base; its mesylate salt has a separate registry identity." }, { "scheme": "Molecular formula", "value_or_pattern": "C19H26N2S", "note": "Formula of the free base, excluding the mesylate counterion." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "The US Food and Drug Administration announced withdrawal of human pergolide products from the US market in 2007 because of serious cardiac valve damage." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Veterinary management of pituitary pars intermedia dysfunction in horses.", "Historical treatment of Parkinson's disease, including use alongside levodopa." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of pergolide free base", "typical_range": "314.49", "unit": "g/mol" }, { "quantity": "Molar mass of anhydrous pergolide mesylate", "typical_range": "410.59", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Human exposure during treatment has been associated with cardiac valvulopathy linked to serotonin 5-HT2B receptor agonism.", "Ergot-associated fibrotic complications can affect tissues outside the heart.", "Dopaminergic adverse effects in humans include nausea, orthostatic hypotension, hallucinations and somnolence.", "Treatment in horses can cause reduced appetite and lethargy.", "Confusing free-base mass with mesylate-salt mass can cause formulation or dosing errors." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Human and veterinary authorizations are distinct, and availability and approved indications depend on jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Pergolide mesylate", "difference": "The methanesulfonate salt of pergolide includes a counterion and has a different formula and molar mass from the free base." }, { "name": "Cabergoline", "difference": "Another ergot-derived dopamine agonist, but a chemically distinct active substance with different pharmacokinetics and authorized uses." }, { "name": "Pramipexole", "difference": "A dopamine agonist that is not an ergot derivative and has a different molecular structure." }, { "name": "Pergolide medicinal product", "difference": "A finished formulation contains pergolide or its salt at a specified strength together with excipients; it is not the isolated substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of pergolide this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the registry intend pergolide to denote only the free base or the active moiety across salts, and is an existing world model already authoritative for that scope?", "Which authoritative EC identifiers, jurisdiction-specific GHS classifications, and occupational exposure limits are established for the free base and mesylate respectively?", "Which experimentally supported melting or decomposition temperatures, solubilities, and solid-form descriptions apply to each material form?", "Which validated methods and specifications establish pergolide assay, stereochemical purity, degradation products, and retest periods?", "What are the current human and veterinary authorization statuses and species restrictions in the jurisdictions this catalogue must support?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 19, "questions": 29 } }